During manufacturing of biopharmaceuticals prokaryotic and eukaryotic protein expression host systems like E. coli and CHO cells generate a heterogeneous mixture of the desired therapeutic protein and a variety of endogenous ... read more

Chemical and post-translational modifications, including crystallizable fragment (Fc) glycosylation, that occur in the marketed IgG1 antibody trastuzumab have been extensively reviewed. Glycosylation of therapeutic ... read more